Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Vespignani

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Cancer|November 15, 1989
Evaluation of serum levels of soluble interleukin-2 receptor in patients with chronic lymphoproliferative disorders of T-lymphocytesR Zambello, G Pizzolo, L Trentin, et al.
Leukemia|November 1, 1991
Different mechanisms of activation of proliferating CD3+ cells in patients with lymphoproliferative disease of granular lymphocytesR Zambello, M A Cassatella, L Trentin, et al.
Cancer|December 15, 1987
The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditionsG Semenzato, F Pandolfi, T Chisesi, et al.
Journal of Clinical & Laboratory Immunology|July 1, 1986
The analysis of expanded cells from patients with lymphoproliferative disorders of granular lymphocytes may help to clarify the NK cell differentiationR Zambello, T Chisesi, G De Rossi, et al.
Leukemia & Lymphoma|July 28, 2016
Treatment of Early Stage Hodgkin's Disease According to Risk FactorsT Chisesi, M Vespignani, G Capnist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1994
MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study GroupM R Sertoli, G Santini, T Chisesi, et al.
Haematologica|December 10, 1999
Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical studyR Bassan, E Pogliani, T Lerede, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|June 26, 2001
Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groupsR Bassan, E Pogliani, P Casula, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study GroupG Santini, L Salvagno, P Leoni, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Cancer|November 15, 1989
Evaluation of serum levels of soluble interleukin-2 receptor in patients with chronic lymphoproliferative disorders of T-lymphocytesR Zambello, G Pizzolo, L Trentin, et al.
Leukemia|November 1, 1991
Different mechanisms of activation of proliferating CD3+ cells in patients with lymphoproliferative disease of granular lymphocytesR Zambello, M A Cassatella, L Trentin, et al.
Cancer|December 15, 1987
The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditionsG Semenzato, F Pandolfi, T Chisesi, et al.
Journal of Clinical & Laboratory Immunology|July 1, 1986
The analysis of expanded cells from patients with lymphoproliferative disorders of granular lymphocytes may help to clarify the NK cell differentiationR Zambello, T Chisesi, G De Rossi, et al.
Leukemia & Lymphoma|July 28, 2016
Treatment of Early Stage Hodgkin's Disease According to Risk FactorsT Chisesi, M Vespignani, G Capnist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1994
MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study GroupM R Sertoli, G Santini, T Chisesi, et al.
Haematologica|December 10, 1999
Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical studyR Bassan, E Pogliani, T Lerede, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|June 26, 2001
Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groupsR Bassan, E Pogliani, P Casula, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study GroupG Santini, L Salvagno, P Leoni, et al.
Pageof 2